Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model

por Julander, Justin G., Testori, Marco, Cheminay, Cédric, Volkmann, Ariane
Publicado 2018

VS411 Reduced Immune Activation and HIV-1 RNA Levels in 28 Days: Randomized Proof-of-Concept Study for AntiViral-HyperActivation Limiting Therapeutics

por Lori, Franco, De Forni, Davide, Katabira, Elly, Baev, Denis, Maserati, Renato, Calarota, Sandra A., Cahn, Pedro, Testori, Marco, Rakhmanova, Aza, Stevens, Michael R.
Publicado 2012

NLRC4 Inflammasome-Driven Immunogenicity of a Recombinant MVA Mucosal Vaccine Encoding Flagellin

por Sanos, Stephanie L., Kassub, Ronny, Testori, Marco, Geiger, Marlene, Pätzold, Juliane, Giessel, Raphael, Knallinger, Johanna, Bathke, Barbara, Gräbnitz, Fabienne, Brinkmann, Kay, Chaplin, Paul, Suter, Mark, Hochrein, Hubertus, Lauterbach, Henning
Publicado 2018

Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies

por Medina-Echeverz, José, Hinterberger, Maria, Testori, Marco, Geiger, Marlene, Giessel, Raphael, Bathke, Barbara, Kassub, Ronny, Gräbnitz, Fabienne, Fiore, Giovanna, Wennier, Sonia T., Chaplin, Paul, Suter, Mark, Hochrein, Hubertus, Lauterbach, Henning
Publicado 2019